NurExone Biologic Appoints David Stolick To Board of Directors, Strengthens Board With Finance and Healthcare Veteran

NurExone Biologic has appointed David Stolick to its Board of Directors, effective July 28, 2026. Stolick succeeds the late James "Jay" Richardson, whose leadership helped guide the company through its early development. NurExone is focused on developing exosome-based regenerative therapies for potential applications in regenerative medicine.

Stolick brings extensive experience in finance, capital markets, mergers and acquisitions, and healthcare company leadership. He previously served as Vice President of Finance at V-Wave Ltd., a U.S.-Israeli medical device company that was acquired by Johnson & Johnson in October 2024.

“Jay was much more than a director. He was a dealmaker, a trusted business advisor, our presence on the ground in Canada, and a true friend of the Company. He believed deeply in our technology, our team, and the opportunity we are working to build. May his memory be for a blessing,” said Yoram Drucker, Chairman of the Board of NurExone. “We also welcome David to the Board. He understands what it takes to move from innovative technology to disciplined execution, and we believe his perspective will be an important addition as NurExone continues to grow.” 

Earlier in his career, Stolick held senior financial roles, including Chief Financial Officer at Exalenz Bioscience and BrainStorm Cell Therapeutics. He also served as Corporate Controller at M-Systems, adding further experience in financial management and corporate operations to his background.

“I am honoured to join NurExone’s Board,” said David Stolick. “I look forward to contributing my financial and M&A experience to support the Company’s growth strategy, disciplined execution, and long-term shareholder value.” 

Stolick holds a B.A. in Economics and Accounting from Ben-Gurion University and is a Certified Public Accountant. His appointment is expected to add financial and strategic expertise to NurExone's board as the company continues advancing its regenerative medicine pipeline.